OXCT1

Across TCGA pan-cancer cohorts, OXCT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OXCT1 data layer compared with 17 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher OXCT1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated OXCT1 expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM, HNSC, and PDAC are the cancer types where OXCT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.913	0.569	.001	12	view →
HNSC	DFS	Tertile	All	0.907	0.976	.021	11	view →
PDAC	DFS	Median	II,III,IV	0.901	0.658	.014	9	view →
LUAD	DFS	Median	III,IV	1.000	0.498	.017	4	view →
LSCC	OS	Median	III,IV	0.996	0.720	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OXCT1–GBM (DFS)

Open the GBM breakdown →